Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

The AleCardio trial aimed to characterize the efficacy and safety of peroxisome proliferator‐activated receptor‐αγ agonist aleglitazar in patients with type 2 diabetes mellitus and acute coronary syndrome. The trial terminated early because of futility and safety signals. We evaluated whether the safety signals could be attributed to increased exposure to aleglitazar.

• Publication year

  2019

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2019-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.13862PMID 31468659PMCID 6916612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

  2019cited by this paper
• Review for "Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial"

  2019cited by this paper
• Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

  2016cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

  2016cited by this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016cited by this paper
• CHAPTER 26:Aleglitazar: A Case Study

  2014cited by this paper
• Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

  2014cited by this paper
• Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

  2013influential reference
• Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods

  2013cited by this paper
• PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

  2012cited by this paper
• Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.

  2012cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo‐Controlled Clinical Study

  2010cited by this paper
• Pioglitazone: side effect and safety profile

  2010cited by this paper
• Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

  2009cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper
• For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt

  2001cited by this paper
• Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes.

  1993cited by this paper

• Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

  2020cites this paper
• Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper